Favipiravir is an oral antiviral selectively inhibiting RNA Polymerase necessary for viral replication.

I. Novel or re-emerging influenza virus infections.
II. Investigational use for novel corona virus, SARS-CoV-2 infection.

As directed by registered medical practitioner only.

Since the elderly often have reduced physiological functions, Favipiravir should be administered with care to them by monitoring their general conditions.

Favipiravir has not been administered to children.

Favipiravir is distributed in sperm. When administering the drug to male patients, explain fully the risks and instruct thoroughly to use most effective contraceptive methods in sexual intercourse during and for 7 days after the end of treatment (men must wear a condom). In addition, instruct not to have sexual intercourse with pregnant women.

Since early embryonic deaths and teratogenicity have been observed in animal studies for Favipiravir, do not administer the drug to women known or suspected to be pregnant. When administering Favipiravir to women of childbearing potential, confirm a negative pregnancy test result before starting the treatment. Explain fully the risks and instruct thoroughly to use most effective contraceptive methods with her partner during and for 7 days after the end of the treatment. If pregnancy is suspected during the treatment, instruct to discontinue the treatment immediately and to consult a doctor.

When administering Favipiravir to lactating women, instruct to stop lactating. The major metabolite of Favipiravir, a hydroxylated form, was found to be distributed in breast milk.

Women known or suspected to be pregnant. Early embryonic deaths and teratogenicity have been observed in animal studies. Patients with the history of hypersensitivity to any ingredients of the drug.

Favipiravir is not metabolized by cytochrome P-450 (CYP), mostly metabolized by aldehyde oxidase (AO), and partly metabolized by xanthine oxidase (XO). The drug inhibits AO and CYP2C8, but does not induce CYP. Potential drug-drug interaction due to AO inhibition should not be ignored in the clinical setting. When combined with Favipiravir, the recommended maximum daily doses of acetaminophen is 3 g.

There is increase of plasma level of Favipiravir in patients with liver function impairment. Inactive oxidative metabolite T-705 M1 is excreted by the kidneys. Caution should be taken while giving Favipiravir to renal and hepatic impaired patients.

Keep in a dry place at a temperature below 30°C protected from light and moisture. Keep away from the reach of children and pets.

1 Bottle × 122 Tablets.